Juvenile idiopathic arthritis

Archives of Disease in Childhood: Education and Practice Edition

Volumn 91, Issue 2, 2006, Pages

  McCann, Liza J ^a   Wedderburn, Lucy R ^b   Hasson, Nathan ^b  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FELDENE MELT; FOLINIC ACID; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; LIVER ENZYME; MELOXICAM; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SALAZOSULFAPYRIDINE; SOLUSPAN; TOLMETIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; AMYLOIDOSIS; ANOREXIA; ANXIETY; ARTHRALGIA; ATROPHY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL ARTHRITIS; BLINDNESS; CALCIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DEMYELINATING DISEASE; DENTITION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE CLASSIFICATION; DOSE RESPONSE; ENTERITIS; ERYTHROPHAGOCYTOSIS; GASTROINTESTINAL SYMPTOM; GRANULOMATOSIS; GROWTH DISORDER; HEADACHE; HUMAN; IMMUNOMODULATION; INCIDENCE; INFECTION; INJECTION SITE REACTION; INJURY; JOINT CONTRACTURE; JOINT PROSTHESIS; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LEG LENGTH INEQUALITY; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LUPUS LIKE SYNDROME; LYME DISEASE; LYMPHOMA; META ANALYSIS; MOOD CHANGE; MOUTH ULCER; MUSCULOSKELETAL PAIN; NAUSEA; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL DISORDER; RADIOGRAPHY; RASH; REACTIVE ARTHRITIS; REITER SYNDROME; REVIEW; RHEUMATIC FEVER; RHINITIS; SCOLIOSIS; SIDE EFFECT; SLEEP DISORDER; SOCIAL BEHAVIOR; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VASCULITIS; VOMITING;

EID: 33746901995     PISSN: 17430585     EISSN: None     Source Type: Journal    
DOI: 10.1136/adc.2004.066050     Document Type: Review

References (80)

1. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41:1428-35.
2. Flato B, Aasland A, Vinje O, et al. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998;25:366-75.
3. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14.
4. Takei S, Imanaka H, Shigemori M, et al. Incidence and factors relating to remission in children with juvenile rheumatoid arthritis (JRA) [abstract]. Arthr Rheum 1998;41(suppl 9):S49.
5. Schneider R, Lang BA, Reilly BJ, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 1992;120:200-5.
6. Modesto C, Woo P, Garcia-Consuegra J, et al. Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin Exp Rheumatol 2001;19:211-7.
7. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
8. Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996;23:1975-80.
9. Thomson W, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) 2002;41:1183-9.
10. Kocher MS, Zurakowski D, Kasser JR. Differentiating between septic arthritis and transient synovitis of the hip in children: an evidence-based clinical prediction algorithm. J Bone Joint Surg Am 1999;81:1662-70.
11. Unkila-Kallio L, Kallio MJ, Peltola H. Acute haematogenous osteomyelitis in children in Finland. Finnish Study Group. Ann Med 1993;25:545-9.
12. Aho K, Ahvonen P, Lassus A, et al. HL-A antigen 27 and reactive arthritis. Lancet 1973;2:157.
13. Gerard HC, Schumacher HR, El Gabalawy H, et al. Chlamydia pneumoniae present in the human synovium are viable and metabolically active. Microb Pathog 2000;29:17-24.
14. Ytterberg SR. Viral arthritis. Curr Opin Rheumatol 1999;11:275-80.
15. Nussinovitch M, Harel L, Varsano I. Arthritis after mumps and measles vaccination. Arch Dis Child 1995;72:348-9.
16. Williamson L, Bowness P, Mowat A, et al. Lesson of the week: difficulties in diagnosing acute rheumatic fever-arthritis may be short lived and carditis silent. BMJ 2000;320:362-5.
17. Szer IS, Taylor E, Steere AC. The long-term course of Lyme arthritis in children. N Engl J Med 1991;325:159-63.
18. Cassidy JT, Petty RE. Textbook of pediatric rheumatology, 4th ed. Philadelphia: WB Sounders, 2001:726-79.
19. Cabral DA, Tucker LB. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999;134:53-7.
20. Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr 2004;93:30-6.
21. Chudwin DS, Ammann AJ, Cowan MJ, et al. Significance of a positive antinuclear antibody test in a pediatric population. Am J Dis Child 1983;137:1103-6.
22. Eichenfield AH, Athreya BH, Doughty RA, et al. Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. Pediatrics 1986;78:480-4.
23. Friedman S, Gruber MA. Ultrasonography of the hip in the evaluation of children with seronegative juvenile rheumatoid arthritis. J Rheumatol 2002;29:629-32.
24. Gylys-Morin VM, Graham TB, Blebea JS, et al. Knee in early juvenile rheumatoid arthritis: MR imaging findings. Radiology 2001;220:696-706.
25. Garcia-Morteo O, Maldonado-Cocco JA, Cuttica R, et al. Piroxicam in juvenile rheumatoid arthritis. Fur J Rheumatol Inflamm 1987;8:49-53.
26. Williams PL, Ansell BM, Bell A, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood, Br J Rheumatol 1986;25:67-71.
27. Leak AM, Richter MR, Clemens LE, et al. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 1988;6:157-60.
28. Mulberg AE, Linz C, Bern E, et al. Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr 1993;122:647-9.
29. Foeldvari I, Burgos-Vargas R, Thon A, et al. High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1079-83.
30. Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 1998;41:1210-4.
31. Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999;42:2330-4.
32. Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990;8:413-6.
33. Hupperrz HI, Pfuller H. Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. J Rheumatol 1997;24:1833-7.
34. Balogh Z, Ruzsonyi E. Triamcinolone hexacetonide versus betamethasone. A double-blind comparative study of the long-term effects of intra-articular steroids in patients with juvenile chronic arthritis. Scand J Rheumatol Suppl 1987;67:80-2.
35. Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2003;42:1254-9.
36. Honkanen VE, Rautonen JK, Pelkonen PM. Intra-articular glucocorticoids in early juvenile chronic arthritis. Acta Paediatr 1993;82:1072-4.
37. Picco P, Gattorno M, Buoncompagni A, et al. 6-methylprednisolone 'mini-pulses': a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand J Rheumatol 1996;25:24-7.
38. Kovarsky J. Intermediate-dose intramuscular methylprednisolone acetate in the treatment of rheumatic disease. Ann Rheum Dis 1983;42:308-10.
39. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatrie Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
40. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
41. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
42. Ravelli A, Viola S, Ramenghi B, et al. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998;133:262-5.
43. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
44. Alsufyani K, Ortiz-Alvarez O, Cabral DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004;31:179-82.
45. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
46. Ravelli A, Migliavacca D, Viola S, et al. Efficacy of folinic acid in reducing memotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rneumatol 1999;17:625-7.
47. Cleary AG, McDowell H, Sills JA. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child 2002;86:47-9.
48. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001;28:845-53.
49. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808-16.
50. Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 2001;40:907-13.
51. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997;24:2436-43.
52. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996;129:750-4.
53. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1852-5.
54. Haagsma O, van Riel PL. Combination of second-line antirheumatic drugs. Ann Med 1997;29:169-73.
55. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatrie Rheumatology Collaborative Study Group. J Rheumatol 1994:21:2353-8.
56. Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1996;23:919-24.
57. Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2003;30:1182-90.
58. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
59. Gao JS, Wu H, Tian J. [Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide ana methotrexate]. Zhonghua Er Ke Za Zhi 2003;41:435-8.
60. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
61. Klareskog L, van der HD, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
62. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
63. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002;61:171-3.
64. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthr Rheum 2006;5A:1987-94.
65. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.
66. Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.
67. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
68. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
69. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
70. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
71. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
72. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50.
73. Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Current Opinion in Rheumatology 2003;15:581-6.
74. Sundel RP, Wallace CA, Zurakowski D. Pilot trial of interferon B-1a (AVONEX®) in JRA. [abstract] Arthr Rheum 2001;2(suppl):S272.
75. Coto C, Varela G, Hernandez V, et al. Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Biotherapy 1998;11:15-20.
76. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
77. De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004;63:1318-26.
78. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford) 2002;41:1440-3.
79. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 2002;41:1444-9.
80. Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis. A quality of life study. Arthr Rheum 2003;48:767-775.